RxDoctor Payments Data

Devan Trammel, DO

Family Medicine · Westhampton Beach, NYNPI 1497141709

Payments from drug & device makers

$789in general payments, 2019–2025

Across 30 payments — averaging $26.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$138
  • Merz North America, Inc.$125
  • Lundbeck LLC$111
  • Boehringer Ingelheim$97
  • Novo Nordisk$74
  • AstraZeneca$62
  • plus $183 from 5 others

What the payments were for

  • Food & beverage$789100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$789 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$73,845
Medicare patients
262
Services billed
799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide20$20,437
SynthroidLevothyroxine Sodium15$1,551
Atorvastatin Calcium100$923
Telmisartan33$768
Rosuvastatin Calcium66$600
Levothyroxine Sodium53$517
Amlodipine Besylate78$332
Montelukast Sodium14$332
Albuterol Sulfate HfaAlbuterol Sulfate13$310
Metoprolol Succinate27$309
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide23$226
Lisinopril34$212
Sertraline Hcl21$197
Allopurinol15$195
Losartan Potassium30$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$138$20,43720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Westhampton Beach

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →